A review of the clinical efficacy profile of copolymer 1: New U.S. phase III trial data Kenneth P. Johnson OriginalPaper Pages: S3 - S7
New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis Ruth ArnonMichael SelaDvora Teitelbaum OriginalPaper Pages: S8 - S13
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease Avraham Ben-NunItzhack MendelNicole Kerlero de Rosbo OriginalPaper Pages: S14 - S22
Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel Amos D. KorczynPuiu Nisipeanu OriginalPaper Pages: S23 - S26